RCT | VV116 vs. Nirmatrelvir–Ritonavir for oral treatment of Covid-19

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 – New England Journal of Medicine

Commentaries: 

Study could pave way for new antiviral, as China grapples with Covid wave – STAT

Chinese oral COVID-19 drug equally effective with Paxlovid: study

VV116 Noninferior to Nirmatrelvir-Ritonavir for COVID-19 – HealthDay

Commentary on Twitter

In a Chinese trial involving participants with symptomatic mild-to-moderate Covid-19, VV116 (an oral analogue of remdesivir) was noninferior to nirmatrelvir–ritonavir with respect to the time to sustained clinical recovery.

Read the full study: https://t.co/zckTB3Rvb9 pic.twitter.com/0TVF7hEXjP

— NEJM (@NEJM) December 28, 2022